(lp0
S"Regeneron Pharmaceuticals Inc  and Sanofi  Win FDA Approval of DUPIXENT Smarter Analyst - 15 hours ago Regeneron Pharmaceuticals, Inc.  and Sanofi  announced that the FDA approved DUPIXENT  Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic&nbsp;...Regeneron stock declines 1.5% on new drug's $37000-a-year price tag - MarketWatchFDA approves Regeneron, Sanofi $37000 per year eczema drug - Reuters"
p1
aS"Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis Motley Fool - Mar 7, 2017 Few companies can claim to have helped improve more individuals' eyesight than Regeneron Pharmaceuticals  and Novartis .REGENERON PHARMACEUTICALS,INC.  Files An 8-K Entry into a ... - Market ExclusiveRegeneron Pharmaceuticals Inc  Given a $446.00 Price Target by Piper ... - Chaffey Breeze"
p2
aS'Alexion Pharmaceuticals Inc versus Regeneron Pharmaceuticals Inc Head to Head ... CML News - 18 hours ago Regeneron Pharmaceuticals Inc has a substantially higher fundamental rating then Alexion Pharmaceuticals Inc which has an impact on the head-to-head comparison.'
p3
aS'Vetr Downgrades Regeneron Off Of Share Rise Benzinga - Mar 10, 2017 On Friday the Vetr crowd downgraded their rating for Regeneron Pharmaceuticals Inc  from 4.5 stars , issued 80 days ago, to 4 stars .Regeneron Pharmaceuticals, Inc.  News Impact Score At 90 - Stock ObserverThe Regeneron Pharmaceuticals, Inc.  Shares Sold by GSA Capital Partners LLP - Petro Global News 24'
p4
aS'Regeneron Pharmaceuticals Inc  Given New $412.00 Price Target at BMO ... Chaffey Breeze - 11 hours ago Regeneron Pharmaceuticals logo Regeneron Pharmaceuticals Inc  had its price target upped by equities researchers at BMO Capital Markets to $412.00 in a research report issued to clients and investors on Tuesday.Regeneron Pharmaceuticals Inc.  Rises 2.86% for March 27 - Equities.comAnalyst Activity  Robert W. Baird Reiterates Neutral on Regeneron ... - Market Exclusive'
p5
aS'Regeneron Pharmaceuticals Inc Risk Points versus Health Care CML News - Mar 22, 2017 This is a scatter plot analysis of the critical risk points from the option market for Regeneron Pharmaceuticals Inc  compared to its own past and the Health Care ETF.'
p6
aS'Street Predictions for Regeneron Pharmaceuticals, Inc.  Aiken Advocate - 10 hours ago Street analysts that cover the company have provided target price projections on the stock. The current consensus target price is $427.214 on the stock.'
p7
aS'Equity Insight: Indicator Review for Regeneron Pharmaceuticals Inc  Midway Monitor - 15 hours ago Taking a look at the numbers, Regeneron Pharmaceuticals Inc  has a 14-day Commodity Channel Index  of 24.07. The CCI technical indicator can be used to help determine if a stock is overbought or oversold.'
p8
aS"Regeneron Pharmaceuticals Inc And Sanofi's See Big Dermatitis Drug Progress StockNews.com  - Mar 6, 2017 Regeneron Pharmaceuticals Inc , along with its development partner Sanofi, this morning presented some detailed results from the latest study for their breakthrough dermatitis treatment.Regeneron, Sanofi: DUPIXENT Study In Atopic Dermatitis Shows Positive Data - Nasdaq"
p9
aS'Regeneron Pharmaceuticals Inc.  Rises 3.34% for February 27 Equities.com - Feb 27, 2017 Among the biggest risers on the S&amp;P 500 on Monday February 27 was Regeneron Pharmaceuticals Inc. , popping some 3.34% to a price of $373.05 a share with some 537,859 shares trading hands.How has Regeneron Pharmaceuticals, Inc.: performed recently? - The Daily LeicesterThe Asset Management One Co. Ltd. Boosts Position in Regeneron Pharmaceuticals ... - DailyQuint'
p10
a.